#USA #Los Angeles #Propel Bio #EIT Pharma #Dr. Leen Kawas

Propel Bio Partners Highlights EIT Pharma's Progress

Propel Bio Partners LP, an equity investment firm, has announced significant advancements at EIT Pharma, focusing on innovative treatments for infectious diseases. Founded in January 2025, EIT Pharma is determined to tackle serious medical needs, particularly in chronic hepatitis D and severe acute viral respiratory infections.

Impressive Progress in Drug Development

Under the guidance of CEO Dr. Leen Kawas, EIT Pharma is currently focusing on two major therapies: Lonafarnib and Lambda. Lonafarnib represents a notable innovation as a first-in-class oral therapy specifically aimed at chronic hepatitis D (CHD). Recently, the FDA accepted the New Drug Application for Lonafarnib, following the successful completion of its D-LIVR study—the most extensive clinical trial for CHD, which involved over 400 participants across 21 countries.

Similarly, EIT Pharma's Lambda is undergoing Phase 2 trials aimed at treating severe acute viral respiratory infections. This dedication to addressing unmet medical needs in infectious diseases is part of a broader ethos that Dr. Kawas and her team embody: innovation driven by rigorous science and a patient-centered philosophy.

Dr. Leen Kawas's Visionary Leadership

Dr. Kawas expressed her pride in leading EIT Pharma at such a critical juncture, emphasizing that individuals living with chronic hepatitis D often lack adequate treatment options. “It’s our mission to ensure that no patient is left without the medications they desperately need,” she stated. Her passion for improving the lives of patients has propelled EIT Pharma into a position of promise and potential impact in the healthcare industry.

Supporting this ambitious initiative is Dr. Jeffrey Glenn, co-founder of EIT Pharma, who notes Dr. Kawas's unique blend of entrepreneurial vigor and scientific insight as instrumental in the company’s successful trajectory. With over a decade of proven leadership in biotechnology and a Ph.D. in pharmacology, Dr. Kawas stands at the forefront of EIT’s mission to bring groundbreaking therapies to market.

Propel Bio Partners: A Commitment to Innovation

Founded in Los Angeles and Seattle, Propel Bio Partners LP plays a crucial role in supporting EIT Pharma not just financially but by connecting them with a network of medical experts and operational advisors. This partnership highlights Propel's commitment to nurturing innovative life science companies, paving the way for advancements that could dramatically improve health standards globally.

The synergy between Propel Bio Partners and EIT Pharma signifies a strong dedication to pioneering therapies that could reshape the landscape of infectious disease treatment. With a focus on both scientific rigor and practical applications, these companies are poised to make a meaningful difference in the lives of patients worldwide.

Conclusion

As EIT Pharma forges ahead under the adept leadership of Dr. Kawas, the biotech community and investors alike are eager to watch its progress closely. By addressing the critical unmet needs associated with chronic hepatitis D and other severe infections, EIT Pharma and Propel Bio Partners exemplify how innovative biotechnology can align with profound humanitarian goals, making strides toward a healthier future for countless individuals.